TrialThe Lancet. Oncology2016

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Padmanee Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.